Biomedical Engineering Reference
In-Depth Information
250. Jones RM et al (1996) On-line high-performance liquid chromatographic-electrospray
ionization mass spectrometric method for the study of tamoxifen metabolism. J Chromatogr A
722:249-255
251. Lim CK et al (1997) Identification and mechanism of formation of potentially genotoxic
metabolites of tamoxifen: study by LC-MS/MS. J Pharm Biomed Anal 15:1335-1342
252. Boocock DJ et al (2002) Identification of human CYP forms involved in the activation of
tamoxifen and irreversible binding to DNA. Carcinogenesis 23:1897-1901
253. Mazzarino M et al (2008) A mass spectrometric approach for the study of the metabolism of
clomiphene, tamoxifen and toremifene by liquid chromatography time-of-flight spectros-
copy. Eur J Mass Spectrom 14:171-180
254. Mazzarino M et al (2010) Mass spectrometric characterization of tamoxifene metabolites in
human urine utilizing different scan parameters on liquid chromatography/tandem mass
spectrometry. Rapid Commun Mass Spectrom 24:749-760
255. Teunissen SF et al (2010) Bioanalytical methods for determination of tamoxifen and its phase
I metabolites: a review. Anal Chim Acta 683:21-37
256. Matuszewski BK et al (2003) Strategies for the assessment of matrix effect in quantitative
bioanalytical methods based on HPLC-MS/MS. Anal Chem 75:3019-3030
257. Matuszewski BK (2006) Standard line slopes as a measure of a relative matrix effect in quan-
titative HPLC-MS bioanalysis. J Chromatogr B Analyt Technol Biomed Life Sci 830:
293-300
258. Lindegardh N et al (2008) Development and validation of a liquid chromatographic-tandem
mass spectrometric method for determination of piperaquine in plasma stable isotope labeled
internal standard does not always compensate for matrix effects. J Chromatogr B Analyt
Technol Biomed Life Sci 862:227-236
259. Bonfiglio R et al (1999) The effects of sample preparation methods on the variability of the
electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom
13:1175-1185
260. Viswanathan CT et al (2007) Quantitative bioanalytical methods validation and implementa-
tion: best practices for chromatographic and ligand binding assays. Pharm Res
24:1962-1973
261. Polson C et al (2003) Optimization of protein precipitation based upon effectiveness of pro-
tein removal and ionization effect in liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci 785:263-275
262. Souverain S et al (2004) Protein precipitation for the analysis of a drug cocktail in plasma by
LC-ESI-MS. J Pharm Biomed Anal 35:913-920
263. Ismaiel OA et al (2010) Investigation of endogenous blood plasma phospholipids, cholesterol
and glycerides that contribute to matrix effects in bioanalysis by liquid chromatography/mass
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:3303-3316
264. Van Eeckhaut A et al (2009) Validation of bioanalytical LC-MS/MS assays: evaluation of
matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 877:2198-2207
265. Hewavitharana AK (2011) Matrix matching in liquid chromatography-mass spectrometry
with stable isotope labelled internal standards-is it necessary? J Chromatogr A 1218:
359-361
266. Imatinib Concentration Monitoring Evaluation (I-COME).
http://www.controlled-trials.com/
267. European Treatment and Outcome Study (EUTOS).
http://www.eutos.org
268. ASQUALAB, Paris, France.
http://www.asqualab.com/
269. Guiducci C et al. ISyPeM: Intelligent Integrated Systems for Personalised Medicine.
http://
